All In Biotech

Drug Trial Radar · NCT04516746

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

Last checked: Nov 20, 2026Latest source record: Feb 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 32,450 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

32,450

Actual

Start

Aug 28, 2020

Primary completion

Mar 5, 2021

Study completion Feb 10, 2023

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
Aug 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.

Conditions

  • COVID-19
  • SARS-CoV-2

Interventions

  • AZD1222Biological

    AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein.

  • PlaceboBiological

    Commercially available 0.9% (n/V) saline for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Binary ResponseTime frame: From 15 days post second dose up to data cut-off date (DCO) of 05 March 2021 or study discontinuation or unblinding or receipt of non-study COVID-19 vaccination, up to a maximum of 17 weeks
  2. Number of Participants With Adverse Events (AEs) Post Each Dose of Study InterventionTime frame: From Day 1 up to 28 days post second dose of study intervention, approximately 57 days
  3. Number of Participants With Serious Adverse Events (SAE), Medically Attended Adverse Events (MAAE), and Adverse Event of Special Interest (AESI) Prior to Non-study COVID-19 VaccinationTime frame: From Day 1 up to receipt of non-study COVID-19 vaccination or a maximum of Day 760 for participants without non-study COVID-19 vaccination.
  4. Number of Participants With Local and Systemic Solicited AEs in the Substudy OnlyTime frame: From Day 1 up to 7 days post each dose of study intervention, approximately 14 days

Locations

84 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Berkeley, California

  • Research Site

    El Centro, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    San Francisco, California

  • Research Site

    San Francisco, California

  • Research Site

    Torrance, California

  • Research Site

    Denver, Colorado

  • Research Site

    Danbury, Connecticut

  • Research Site

    Coral Gables, Florida

  • Research Site

    Lake Worth, Florida

  • Research Site

    Miami Lakes, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Honolulu, Hawaii

  • Research Site

    Meridian, Idaho

  • Research Site

    Chicago, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Ankeny, Iowa

  • Research Site

    Fairway, Kansas

  • Research Site

    Kansas City, Kansas

  • Research Site

    Wichita, Kansas

  • Research Site

    Wichita, Kansas

  • Research Site

    Lexington, Kentucky

  • Research Site

    Lake Charles, Louisiana

  • Research Site

    Monroe, Louisiana

  • Research Site

    Baltimore, Maryland

  • Research Site

    Baltimore, Maryland

  • Research Site

    Bethesda, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Royal Oak, Michigan

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Gulfport, Mississippi

  • Research Site

    Butte, Montana

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.